secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001171843-26-001504
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience 2025 revenue $86.6M, net loss $56.7M incl $48M goodwill impairment; permanent CFO appointed
--------------------------------------------------------------------------------

- Q4 revenue $23.7M (down from $24.6M YoY); gross margin 59.7% (up from 57.1%).
- Full-year net loss $56.7M driven by $48.0M goodwill impairment in Q1 2025.
- Adjusted EBITDA $8.1M for FY2025 vs $7.2M in FY2024; operating cash flow $6.7M vs $1.4M.
- Interim CFO Mark Frost appointed permanent CFO effective March 12, 2026.
- Introduced FY2026 guidance for revenue growth from new translational science products; no specific figures provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326001504/0001171843-26-001504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326001504/f8k_031226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer